Search - tctmd.com

Displaying 761 - 780 of 2035

Sort: Relevancy | Date

News Industry News

Medtronic Drug-Coated Balloon Shows Strong Clinical and Economic Benefit in Treatment of Peripheral Artery Disease

September 16, 2014

News Industry News

InspireMD Announces Positive Results from CGuard™ CARENET Trial with 0% MACE reported at 30 Days

September 16, 2014

News Conference News TCT 2014

EXCITE ISR: Laser Atherectomy Superior to Angioplasty Alone for Femoropopliteal In-Stent Restenosis

September 16, 2014

Presentation TCT 2014

Choice of Metallic DES Stents for Bifurcation Stenting

Presenter: Bernard R. Chevalier, Leif Thuesen, Ricardo A. Costa, Francesco Burzotta

September 15, 2014

News Conference News TCT 2014

SECURITY: Six-Month DAPT Noninferior to 12 Months with Second-Generation DES

September 15, 2014

News Conference News TCT 2014

OPTIMIZE: Short-term DAPT Safe 2 Years After ZES Implantation

September 15, 2014

News Industry News

New Study Examines the Optimal Duration Time of Dual Anti-Platelet Therapy in Patients with Second-Generation Drug-Eluting Stents

September 15, 2014

News Conference News TCT 2014

Marie-Claude Morice, MD, Receives 2014 Master Clinical Operator Award

September 15, 2014

News Conference News TCT 2014

Keynote Address Focuses on Newer DES, Problematic Subgroups

September 15, 2014

News Conference News TCT 2014

EES Decrease Restenosis, TVR vs. BMS in Non-STEMI

September 15, 2014

News Conference News TCT 2014

COMBO Stent Achieves Neointimal Regression at 24 Months

September 15, 2014

News Industry News

Abbott Initiates ABSORB IV Trial to Evaluate Quality of Life and Cost Savings of Dissolving Heart Device

September 15, 2014

Presentation TCT 2014

TCT 643: Very Late Stent Thrombosis After Revascularization with the Biolimus-Eluting, Biodegradable Polymer-Coated Nobori Stent Versus Durable Polymer-Coated, Sirolimus-Eluting Stents from the SORT-OUT V Trial

Presenter: Evald H. Christiansen

September 14, 2014

Presentation TCT 2014

TCT 641: Improved Safety and Reduction in Stent Thrombosis After Everolimus-Eluting Stents Versus Sirolimus-Eluting Stents in Patients with Coronary Artery Disease: SORT-OUT IV 5-Year Results

Presenter: Donald Cutlip, Manel Sabate, Elvin Kedhi, Lisette Okkels Jensen

September 14, 2014

Presentation TCT 2014

Focal Treatment of Vulnerable Plaque: Stents, Scaffolds, and Prospect ABSORB

Presenter: Valentin Fuster, Patrick W. Serruys, Gregg W. Stone

September 14, 2014

Presentation TCT 2014

Case #4: My Preferred Technique When 2 Stents are Needed DK Crush

Presenter: Jean Fajadet, Marie-Claude Morice, Seung-Jung Park, Corrado Tamburino, Shao Liang Chen

September 14, 2014

Presentation TCT 2014

Case #3: My Preferred Technique When 2 Stents are Needed - Culotte

Presenter: Jean Fajadet, Marie-Claude Morice, Seung-Jung Park, Corrado Tamburino

September 14, 2014

Presentation TCT 2014

Case #2: My Preferred Technique When 2 Stents are Needed - T or TAP

Presenter: Jean Fajadet, Marie-Claude Morice, Seung-Jung Park, Corrado Tamburino

September 14, 2014

Presentation TCT 2014

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents

Presenter: Gregg W. Stone, Pieter C. Smits, Fernando Alfonso

September 14, 2014

News Conference News TCT 2014

RIBS IV: EES Superior to DEB in Patients with In-Stent Restenosis

September 14, 2014

Advertisement

Medtronic Drug-Coated Balloon Shows Strong Clinical and Economic Benefit in Treatment of Peripheral Artery Disease

InspireMD Announces Positive Results from CGuard™ CARENET Trial with 0% MACE reported at 30 Days

EXCITE ISR: Laser Atherectomy Superior to Angioplasty Alone for Femoropopliteal In-Stent Restenosis

Choice of Metallic DES Stents for Bifurcation Stenting

SECURITY: Six-Month DAPT Noninferior to 12 Months with Second-Generation DES

OPTIMIZE: Short-term DAPT Safe 2 Years After ZES Implantation

New Study Examines the Optimal Duration Time of Dual Anti-Platelet Therapy in Patients with Second-Generation Drug-Eluting Stents

Marie-Claude Morice, MD, Receives 2014 Master Clinical Operator Award

Keynote Address Focuses on Newer DES, Problematic Subgroups

EES Decrease Restenosis, TVR vs. BMS in Non-STEMI

COMBO Stent Achieves Neointimal Regression at 24 Months

Abbott Initiates ABSORB IV Trial to Evaluate Quality of Life and Cost Savings of Dissolving Heart Device

TCT 643: Very Late Stent Thrombosis After Revascularization with the Biolimus-Eluting, Biodegradable Polymer-Coated Nobori Stent Versus Durable Polymer-Coated, Sirolimus-Eluting Stents from the SORT-OUT V Trial

TCT 641: Improved Safety and Reduction in Stent Thrombosis After Everolimus-Eluting Stents Versus Sirolimus-Eluting Stents in Patients with Coronary Artery Disease: SORT-OUT IV 5-Year Results

Focal Treatment of Vulnerable Plaque: Stents, Scaffolds, and Prospect ABSORB

Case #4: My Preferred Technique When 2 Stents are Needed DK Crush

Case #3: My Preferred Technique When 2 Stents are Needed - Culotte

Case #2: My Preferred Technique When 2 Stents are Needed - T or TAP

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents

RIBS IV: EES Superior to DEB in Patients with In-Stent Restenosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content